InsightfulValue
← Home

EBOS Group
EBOS Group

-8.02%

Healthcare & biotech / Healthcare and animal care products


πŸ”§ Tools

βœ… Due Diligence
πŸ”₯ Video Insights

EBOS Group Near A$15: A 40% Collapse β€” Is This Healthcare Stock Finally Cheap?

October 6, 2026

EBOS Group has been crushed. At around A$15.35, the shares are sitting near their 52-week low of A$15.37 and are roughly 43% below the previous high. Yet the underlying business continues to grow. Is the market overlooking what could become a powerful recovery story? First-half fiscal 2026 revenue increased 13% to A$6.77 billion, while underlying earnings before interest, tax, depreciation and amortisation rose 3.2% to A$300 million. Statutory profit increased 13% to A$126.6 million. Management expects stronger cash flow from fiscal 2027 as major capital investment winds down. The problem is profitability. Underlying net profit declined 4.3% in the first half, reflecting investment costs and pressure within the healthcare segment. Investors are also concerned about leverage, capital spending and the competitive pharmacy environment. The dividend provides another reason to watch the stock. EBOS paid 57 New Zealand cents per share for the 2026 interim dividend, while the previous full-year payment was 118.5 cents. The value case is compelling if earnings growth accelerates as investment spending falls. The main risks are thin margins, competitive pressure, debt and weaker consumer spending in animal care. A recovery could be substantial if cash flow improves and margins expand from fiscal 2027. This review is for informational and educational purposes only, not financial advice.

Value investing review - EBOS Group: Undervalued Healthcare Giant or Value Trap?

May 28, 2026

EBOS Group operates behind the scenes of the healthcare industry, distributing pharmaceuticals, medical products, and animal care solutions across Australia and New Zealand. In this video, we break down why the stock price has weakened recently, what the latest earnings reveal, how the company’s dividends and margins are evolving, and whether this healthcare giant could recover in the coming years. InsightfulValue delivers clear, practical analysis of undervalued companies for both beginner and experienced investors. Subscribe for more stock analysis videos and deeper research and hidden value opportunities.

EBOS Group – Defensive Giant at a Discount?

March 26, 2026

EBOS Group’s stock has softened recently, slipping from prior highs as investors reassess growth expectations. The current price reflects caution rather than a deterioration in fundamentals. Recent results show steady revenue growth, supported by resilient demand, while earnings remain stable but not accelerating. Margins are relatively thin but consistent, typical for the sector, and cash generation remains strong. Dividends have been reliable and gradually increasing, offering a stable income component. The decline is driven by lower growth expectations, integration of past acquisitions, and broader market sentiment toward defensive names. From a value perspective, the stock may now appear more attractive due to its stability and predictable cash flows. However, risks include limited margin expansion and slower earnings growth. The bull case is continued steady performance and gradual improvement. The bear case is prolonged stagnation. This review is for informational and educational purposes only, not financial advice.

EBOS Group β€” Discounted Healthcare Distributor or Risky Bet?

November 26, 2025

A quick, clear look at why EBOS Group shares have dropped: contract loss, profit drop, but still diversified operations. Is this a value opportunity or a risk zone?

RUJPUyBHcm 91cDogSXMg VGhpcyBIZW FsdGhjYXJl IFN0b2NrIF VuZGVydmFs dWVkIG9yIG luIFRyb3Vi bGU/

October 15, 2025

In this video, we analyze EBOS Group, a leading healthcare distributor in Australasia, whose stock price has recently declined. We examine the company’s financial performance, dividend history, and the factors contributing to the stock’s downturn. Join us as we explore whether EBOS Group presents an investment opportunity or if caution is warranted.

RUJPUyBHcm 91cDogSXMg dGhlIFN0b2 NrIFByaWNl IERpcCBhIE J1eWluZyBP cHBvcnR1bm l0eT8=

August 28, 2025

In this video, we analyze EBOS Group’s recent stock price decline, examining the factors contributing to its current financial performance. We provide insights into the company’s operations, financials, and potential risks, helping investors make informed decisions.
© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal